We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| SurModics Inc | NASDAQ:SRDX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.06 | -5.96% | 32.49 | 27.81 | 40.72 | 35.21 | 32.335 | 35.21 | 90,444 | 01:00:00 |
From May 2019 to May 2024
Webcast is Live on Thursday, November 9, at 9 a.m. (ET)
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj, president and chief executive officer, and Andy LaFrence, vice president of finance and information systems and chief financial officer, will make a presentation to the investment community at the Canaccord Genuity Medical Technologies and Diagnostics Forum in New York City on Thursday, November 9, 2017, at 9 a.m. ET (8 a.m. CT).
A live audio webcast of the presentation will be available by going to the investor relations portion of the Company’s website at www.surmodics.com and clicking on the webcast icon. The webcast will be archived on the Company’s website for 90 days following the live presentation.
About Surmodics, Inc.
Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic (IVD) tests and microarrays. Following two recent acquisitions of Creagh Medical and NorMedix, the Company is executing a key growth strategy for its medical device business by expanding to offer total intravascular product solutions to its medical device customers. The combination of proprietary surface technologies, along with enhanced device design, development and manufacturing capabilities, enables Surmodics to significantly increase the value it offers with highly differentiated intravascular solutions designed and engineered to meet the most demanding requirements. With this focus on offering total solutions, Surmodics’ mission remains to improve the detection and treatment of disease. Surmodics is headquartered in Eden Prairie, Minnesota. For more information about the company, visit www.surmodics.com. The content of Surmodics’ website is not part of this press release or part of any filings that the company makes with the SEC.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171026005293/en/
Surmodics, Inc.Andy LaFrence, 952-500-7000ir@surmodics.com
1 Year SurModics Chart |
1 Month SurModics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
